Thrombosis and Haemostasis: Clinical Advances
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Vascular Medicine".
Deadline for manuscript submissions: closed (20 March 2026) | Viewed by 5771
Special Issue Editor
2. Northern Clinical Diagnostics and Thrombovascular Research (NECTAR) Centre, Northern Health, Epping, VIC 3076, Australia
3. Department of Medicine (Northern Health), University of Melbourne, Epping, VIC 3076, Australia
4. Australian Centre for Blood Diseases, Monash University, Melbourne, VIC 3004, Australia
5. School of Health and Biomedical Sciences, RMIT—The Royal Melbourne Institute of Technology, Melbourne, VIC 3000, Australia
Interests: venous thrombosis; thrombosis; cardiovascular disease; anticoagulation
Special Issue Information
Dear Colleagues,
In patients with a first episode of unprovoked VTE, the risk of recurrence can be as high as 25% at five years and 36% at 10 years. Although continued anticoagulation reduces the risk of recurrence, it must be carefully weighed against the risk of bleeding, estimated at 1–4% per year. Existing prediction models for predicting first VTE, subsequent recurrence, and bleeding risks have methodological limitations and insufficient predictive accuracy. A personalised risk assessment and tailored anticoagulation management is crucial to prevent recurrence without unnecessarily putting lower-risk patients at increased risk of anticoagulation-related bleeding. Beyond the recommended minimal duration of anticoagulation, there is no universally recommended long-term duration of anticoagulation, as the risk-benefit differs between individuals. The addition of novel biomarkers in combination with clinical risk assessment models may improve the clinician’s ability to predict such risks at an individual level.
While direct oral anticoagulants (DOACs) have revolutionised anticoagulation management in VTE, the use of DOACs, including the duration and optimal dosing in the setting of patients with cardiovascular comorbidities (e.g., stable atherosclerosis disease, renal impairment), is still under debate. Furthermore, there is increasing interest in targeting other upstream coagulation factors, such as the inhibition of factors XI and XII, as alternative anticoagulation agents with potentially lower bleeding risks. Another area of highlight is the treatment approach for intermediate-risk PE, in which our understanding of best practises remains limited. There is emerging evidence demonstrating improved short-term outcomes following endovascular treatments, but there remains a paucity of evidence of the safety and efficacy of these approaches compared to conservative therapies in the short and long term.
In this Special Issue, we welcome authors to submit papers that address the current and future state of the art in the management of venous and arterial thrombosis.
Dr. Hui Yin Lim
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- venous thrombosis
- biomarkers
- bleeding
- direct oral anticoagulants
- pulmonary embolism
- factor XI inhibitors
- factor XII inhibitors
- endovascular treatment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
